Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab + Rituximab followed by R-CHOP in PMBL
NCT06742502Phase 2Recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Nov 2024
- Primary completion
- Dec 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sintilimab in primary mediastinal B-cell lymphoma (PMBCL), sponsored by Sun Yat-sen University. Primary endpoint: Complete Response Rate at 36 months. Started Nov 2024; status: recruiting.
02
Drugs
sintilimab
03
Conditions
primary mediastinal B-cell lymphoma (PMBCL)
Beyond the preview
Go deeper on NCT06742502.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06742502.